Your browser doesn't support javascript.
loading
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson, Avia D; Parthasarathy, Prerana Bangalore; Stabellini, Nickolas; Mitchell, Carley; Pavicic, Paul G; Fu, Pingfu; Rupani, Amit; Husic, Hana; Rayman, Patricia A; Swaidani, Shadi; Abraham, Jame; Budd, G Thomas; Moore, Halle; Al-Hilli, Zahraa; Ko, Jennifer S; Baar, Joseph; Chan, Timothy A; Alban, Tyler; Diaz-Montero, C Marcela; Montero, Alberto J.
Afiliación
  • Wilkerson AD; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Parthasarathy PB; Cleveland Clinic Digestive Disease & Surgery Institute, Department of General Surgery, Cleveland, Ohio.
  • Stabellini N; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Mitchell C; Graduate Education Office, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • Pavicic PG; University Hospitals Cleveland Medical Center, Department of Internal Medicine, Cleveland, Ohio.
  • Fu P; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Rupani A; Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, Ohio.
  • Husic H; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Rayman PA; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Swaidani S; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Abraham J; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Budd GT; Cleveland Clinic Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland, Ohio.
  • Moore H; Cleveland Clinic Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland, Ohio.
  • Al-Hilli Z; Cleveland Clinic Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland, Ohio.
  • Ko JS; Cleveland Clinic Digestive Disease & Surgery Institute, Department of General Surgery, Cleveland, Ohio.
  • Baar J; Cleveland Clinic Pathology & Laboratory Medicine, Department of Anatomic Pathology, Cleveland, Ohio.
  • Chan TA; University Hospitals/Seidman Cancer Center Case Western Reserve University, Cleveland, Ohio.
  • Alban T; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Diaz-Montero CM; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
  • Montero AJ; Cleveland Clinic Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, Ohio.
Clin Cancer Res ; 30(1): 82-93, 2024 01 05.
Article en En | MEDLINE | ID: mdl-37882661
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article